SCHEMBL22409403

SCHEMBL22409403

CC(C)OP(=O)(CN1CCN(CC[C@H](CSc2ccccc2)NC(=O)O)CC1)OC(C)C

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.39
MTNR1B P49286 3/20 0.39
BCL2L1 Q07817 6/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KMT2A Q03164 2/20 0.35
GPR55 Q9Y2T6 2/20 0.35
HSD17B10 Q99714 1/20 0.34
BCL2 P10415 4/20 0.34
BCL2L2 Q92843 2/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.33
MCL1 Q07820 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22409404 1.00 MTNR1A (0.39) MTNR1AMTNR1BBCL2L1KDM4EALDH1A1
SCHEMBL22409436 0.90 BCL2L1 (0.38) MTNR1AMTNR1BBCL2L1KDM4EALDH1A1
SCHEMBL22409437 0.90 BCL2L1 (0.38) MTNR1AMTNR1BBCL2L1KDM4EALDH1A1
SCHEMBL22409442 0.88 ALDH1A1 (0.39) MTNR1AMTNR1BBCL2L1KDM4EALDH1A1
SCHEMBL22409444 0.88 ALDH1A1 (0.39) MTNR1AMTNR1BBCL2L1KDM4EALDH1A1
SCHEMBL22409469 0.82 HTR4 (0.39) MTNR1AMTNR1BBCL2L1KDM4EALDH1A1
SCHEMBL22409468 0.82 HTR4 (0.39) MTNR1AMTNR1BBCL2L1KDM4EALDH1A1
SCHEMBL22409465 0.80 SIGMAR1 (0.39) BCL2L1KDM4EALDH1A1
SCHEMBL21523434 0.78 HSD17B10 (0.54) BCL2L1KDM4EALDH1A1NPC1RAB9A
SCHEMBL21523433 0.78 HSD17B10 (0.54) BCL2L1KDM4EALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders UNITY BIOTECHNOLOGY, INC. (US) 2021-09-07 US disclosed
US-20200291050-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS UNITY BIOTECHNOLOGY, INC. 2020-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders ACAT1, ARSA, GLA MTNR1A 1154/4885MTNR1B 1097/4885BCL2L1 3463/4885
US-20200291050-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS ACAT1, ARSA, GLA MTNR1A 1154/4885MTNR1B 1097/4885BCL2L1 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.